When is MRSA coverage indicated for community-acquired pneumonia?

• A. Never cover MRSA for CAP.
• B. In mild CAP with no risk factors for MRSA.
• C. In severe disease, risk factors for MRSA (e.g., prior MRSA infection), aspiration with sputum purulence, or high local MRSA prevalence.
• D. Always cover MRSA for all CAP.

Answer: (C)

MRSA coverage in community-acquired pneumonia is not routine; it’s reserved for situations where MRSA is more likely. The best approach is to consider MRSA-targeted antibiotics when the pneumonia is severe or when patient-specific factors increase the likelihood of MRSA. Specifically, if the illness is severe (often needing intensive care or presenting with features of complicated pneumonia), or if there are risk factors such as a prior MRSA infection or colonization, recent healthcare exposure, aspiration with purulent sputum, or a high local prevalence of MRSA, then adding MRSA coverage is warranted. In mild CAP without these risk factors, MRSA is unlikely to be the culprit, and broad MRSA coverage can expose patients to unnecessary toxicity and antibiotic resistance without benefit. If MRSA coverage is started in the appropriate scenario, it should be reassessed and de-escalated once culture results or rapid diagnostics exclude MRSA.